$3.40
0.051.49%
At close: May 15, 5:00 PM EST
$3.41
0.0050.15%
After Hours: May 15, 4:57 PM EST
Cytek Biosciences Inc Stock Guidance
CTKBNASDAQ
Cytek Biosciences (CTKB) last issued guidance on May 7, 2026 for fiscal year 2026. The company guided revenue in the range of $205.00M - $212.00M for the period.
Compared to prior guidance, Cytek Biosciences maintained its revenue forecast from a prior range of $205.00M - $212.00M.
Cytek Biosciences has issued 23 guidance updates between June 22, 2022 and May 7, 2026. During this period, the company raised its outlook 5 times and lowered it 7 times, providing investors with insight into management's evolving expectations.
Latest Guidance Date
May 7, 2026
Guidance Period
Full Year 2026
Revenue Guidance Range
$205.00M - $212.00M
Cytek Biosciences Guidance History
Review all historical guidance issued by Cytek Biosciences, including EPS and revenue forecasts across quarterly and annual periods.
Loading calendar...
FAQ
What is the most recent guidance for Cytek Biosciences (CTKB)?
The most recent guidance for Cytek Biosciences (CTKB) was reported on May 7, 2026 for the fiscal year 2026. Cytek Biosciences forecasted revenue between $205.00M and $212.00M for the period.
What revenue range did Cytek Biosciences (CTKB) guide for?
Cytek Biosciences (CTKB) guided revenue in the range of $205.00M to $212.00M for the fiscal year 2026.
Did Cytek Biosciences (CTKB) raise or lower guidance?
Cytek Biosciences (CTKB) maintained its revenue guidance from a prior range of $205.00M - $212.00M to $205.00M - $212.00M for the fiscal year 2026.
When did Cytek Biosciences (CTKB) last issue guidance?
Cytek Biosciences (CTKB) last issued guidance on May 7, 2026 for the fiscal year 2026.
